266 related articles for article (PubMed ID: 24736461)
1. MLL fusion-driven activation of CDK6 potentiates proliferation in MLL-rearranged infant ALL.
van der Linden MH; Willekes M; van Roon E; Seslija L; Schneider P; Pieters R; Stam RW
Cell Cycle; 2014; 13(5):834-44. PubMed ID: 24736461
[TBL] [Abstract][Full Text] [Related]
2. Requirement for CDK6 in MLL-rearranged acute myeloid leukemia.
Placke T; Faber K; Nonami A; Putwain SL; Salih HR; Heidel FH; Krämer A; Root DE; Barbie DA; Krivtsov AV; Armstrong SA; Hahn WC; Huntly BJ; Sykes SM; Milsom MD; Scholl C; Fröhling S
Blood; 2014 Jul; 124(1):13-23. PubMed ID: 24764564
[TBL] [Abstract][Full Text] [Related]
3. Identification of genes transcriptionally responsive to the loss of MLL fusions in MLL-rearranged acute lymphoblastic leukemia.
van der Linden MH; Seslija L; Schneider P; Driessen EM; Castro PG; Stumpel DJ; van Roon E; de Boer J; Williams O; Pieters R; Stam RW
PLoS One; 2015; 10(3):e0120326. PubMed ID: 25793396
[TBL] [Abstract][Full Text] [Related]
4. Expression of MLL-AF4 or AF4-MLL fusions does not impact the efficiency of DNA damage repair.
Castaño J; Herrero AB; Bursen A; González F; Marschalek R; Gutiérrez NC; Menendez P
Oncotarget; 2016 May; 7(21):30440-52. PubMed ID: 27119507
[TBL] [Abstract][Full Text] [Related]
5. Frequencies and prognostic impact of RAS mutations in MLL-rearranged acute lymphoblastic leukemia in infants.
Driessen EM; van Roon EH; Spijkers-Hagelstein JA; Schneider P; de Lorenzo P; Valsecchi MG; Pieters R; Stam RW
Haematologica; 2013 Jun; 98(6):937-44. PubMed ID: 23403319
[TBL] [Abstract][Full Text] [Related]
6. Bortezomib suppresses self-renewal and leukemogenesis of leukemia stem cell by NF-ĸB-dependent inhibition of CDK6 in MLL-rearranged myeloid leukemia.
Zhou B; Qin Y; Zhou J; Ruan J; Xiong F; Dong J; Huang X; Yu Z; Gao S
J Cell Mol Med; 2021 Mar; 25(6):3124-3135. PubMed ID: 33599085
[TBL] [Abstract][Full Text] [Related]
7. Leukemic fusion genes MLL/AF4 and AML1/MTG8 support leukemic self-renewal by controlling expression of the telomerase subunit TERT.
Gessner A; Thomas M; Castro PG; Büchler L; Scholz A; Brümmendorf TH; Soria NM; Vormoor J; Greil J; Heidenreich O
Leukemia; 2010 Oct; 24(10):1751-9. PubMed ID: 20686504
[TBL] [Abstract][Full Text] [Related]
8. Specific Antileukemic Activity of PD0332991, a CDK4/6 Inhibitor, against Philadelphia Chromosome-Positive Lymphoid Leukemia.
Nemoto A; Saida S; Kato I; Kikuchi J; Furukawa Y; Maeda Y; Akahane K; Honna-Oshiro H; Goi K; Kagami K; Kimura S; Sato Y; Okabe S; Niwa A; Watanabe K; Nakahata T; Heike T; Sugita K; Inukai T
Mol Cancer Ther; 2016 Jan; 15(1):94-105. PubMed ID: 26637365
[TBL] [Abstract][Full Text] [Related]
9. The trithorax protein partner menin acts in tandem with EZH2 to suppress C/EBPα and differentiation in MLL-AF9 leukemia.
Thiel AT; Feng Z; Pant DK; Chodosh LA; Hua X
Haematologica; 2013 Jun; 98(6):918-27. PubMed ID: 23349306
[TBL] [Abstract][Full Text] [Related]
10. Crosstalk between 14-3-3θ and AF4 enhances MLL-AF4 activity and promotes leukemia cell proliferation.
Fioretti T; Cevenini A; Zanobio M; Raia M; Sarnataro D; Salvatore F; Esposito G
Cell Oncol (Dordr); 2019 Dec; 42(6):829-845. PubMed ID: 31493143
[TBL] [Abstract][Full Text] [Related]
11. Functional diversity of inhibitors tackling the differentiation blockage of MLL-rearranged leukemia.
Brzezinka K; Nevedomskaya E; Lesche R; Steckel M; Eheim AL; Haegebarth A; Stresemann C
J Hematol Oncol; 2019 Jun; 12(1):66. PubMed ID: 31253180
[TBL] [Abstract][Full Text] [Related]
12. Identification of CD34+ and CD34- leukemia-initiating cells in MLL-rearranged human acute lymphoblastic leukemia.
Aoki Y; Watanabe T; Saito Y; Kuroki Y; Hijikata A; Takagi M; Tomizawa D; Eguchi M; Eguchi-Ishimae M; Kaneko A; Ono R; Sato K; Suzuki N; Fujiki S; Koh K; Ishii E; Shultz LD; Ohara O; Mizutani S; Ishikawa F
Blood; 2015 Feb; 125(6):967-80. PubMed ID: 25538041
[TBL] [Abstract][Full Text] [Related]
13. CDKN1A-mediated responsiveness of MLL-AF4-positive acute lymphoblastic leukemia to Aurora kinase-A inhibitors.
Chen YP; Lin HJ; Chen JS; Tsai MY; Hsieh HP; Chang JY; Chen NF; Chang KC; Huang WT; Su WC; Yang ST; Chang WC; Hung LY; Chen TY
Int J Cancer; 2014 Aug; 135(3):751-62. PubMed ID: 24382688
[TBL] [Abstract][Full Text] [Related]
14. Potent obatoclax cytotoxicity and activation of triple death mode killing across infant acute lymphoblastic leukemia.
Urtishak KA; Edwards AY; Wang LS; Hudome A; Robinson BW; Barrett JS; Cao K; Cory L; Moore JS; Bantly AD; Yu QC; Chen IM; Atlas SR; Willman CL; Kundu M; Carroll AJ; Heerema NA; Devidas M; Hilden JM; Dreyer ZE; Hunger SP; Reaman GH; Felix CA
Blood; 2013 Apr; 121(14):2689-703. PubMed ID: 23393050
[TBL] [Abstract][Full Text] [Related]
15. Nuclear FGFR2 Interacts with the MLL-AF4 Oncogenic Chimera and Positively Regulates
Fioretti T; Cevenini A; Zanobio M; Raia M; Sarnataro D; Cattaneo F; Ammendola R; Esposito G
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33924850
[TBL] [Abstract][Full Text] [Related]
16. miR-130b and miR-128a are essential lineage-specific codrivers of t(4;11) MLL-AF4 acute leukemia.
Malouf C; Antunes ETB; O'Dwyer M; Jakobczyk H; Sahm F; Landua SL; Anderson RA; Soufi A; Halsey C; Ottersbach K
Blood; 2021 Nov; 138(21):2066-2092. PubMed ID: 34111240
[TBL] [Abstract][Full Text] [Related]
17. A human fetal liver-derived infant MLL-AF4 acute lymphoblastic leukemia model reveals a distinct fetal gene expression program.
Rice S; Jackson T; Crump NT; Fordham N; Elliott N; O'Byrne S; Fanego MDML; Addy D; Crabb T; Dryden C; Inglott S; Ladon D; Wright G; Bartram J; Ancliff P; Mead AJ; Halsey C; Roberts I; Milne TA; Roy A
Nat Commun; 2021 Nov; 12(1):6905. PubMed ID: 34824279
[TBL] [Abstract][Full Text] [Related]
18. ZNF521 sustains the differentiation block in MLL-rearranged acute myeloid leukemia.
Germano G; Morello G; Aveic S; Pinazza M; Minuzzo S; Frasson C; Persano L; Bonvini P; Viola G; Bresolin S; Tregnago C; Paganin M; Pigazzi M; Indraccolo S; Basso G
Oncotarget; 2017 Apr; 8(16):26129-26141. PubMed ID: 28412727
[TBL] [Abstract][Full Text] [Related]
19. Pro-B-cell to pre-B-cell development in B-lineage acute lymphoblastic leukemia expressing the MLL/AF4 fusion protein.
Bertrand FE; Vogtenhuber C; Shah N; LeBien TW
Blood; 2001 Dec; 98(12):3398-405. PubMed ID: 11719380
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcome and monitoring of minimal residual disease in patients with acute lymphoblastic leukemia expressing the MLL/ENL fusion gene.
Elia L; Grammatico S; Paoloni F; Vignetti M; Rago A; Cenfra N; Mecarocci S; Mancini M; Luciani M; Di Raimondo F; Cazzaniga G; Matarazzo M; Moleti ML; Santoro L; Gaidano G; Foà R; Mandelli F; Cimino G
Am J Hematol; 2011 Dec; 86(12):993-7. PubMed ID: 21953510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
